Who
Una S. Ryan
Director
Company insider
Files Form 4 as: Director, RenovoRx; Director, Quince Therapeutics; Director, Albany Molecular Research; President & CEO, Celldex Therapeutics.
In numbers
- Trades disclosed
- 70
- Buys
- 3
- Sells
- 0
- Bought
- $91K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 3 Jan 2006
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,924 at $0.00 | filing |
| 1 Oct 2025filed 2 Oct 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,640 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 1 Oct 2023filed 2 Oct 2023 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 24 May 2023filed 26 May 2023 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 1 Oct 2022filed 4 Oct 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | IRLA IRulya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 22 Apr 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $25K26,838 at $0.9315 | filing |
| 22 Apr 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $26K16,206 at $1.62 | filing |
| 22 Apr 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $25K26,838 at $0.93 | filing |
| 22 Apr 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $26K16,206 at $1.62 | filing |
| 10 Mar 2022filed 14 Mar 2022 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,582 at $0.00 | filing |
| 3 Mar 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $200K47,789 at $4.19 | filing |
| 3 Mar 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $25K6,332 at $3.95 | filing |
| 3 Mar 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $200K47,789 at $4.19 | filing |
| 3 Mar 2022filed 24 Jun 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code J | $25K6,332 at $3.95 | filing |
| 1 Oct 2021filed 5 Oct 2021 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,154 at $0.00 | filing |
| 16 Jun 2021filed 17 Jun 2021 | IRLA IRulya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,029 at $0.00 | filing |
News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst ConferenceIRLA · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Una S. Ryan; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.